Skip to main content
Premium Trial:

Request an Annual Quote

FDA Authorizes Pooled Sampling With Applied BioCode Coronavirus Test

NEW YORK — The US Food and Drug Administration on Monday reissued an Emergency Use Authorization for Applied BioCode's SARS-CoV-2 Assay to allow the test to be used with pooled samples.

The PCR-based test, which runs on Applied Biocode's MDx-3000 instrument, was first authorized in June for the detection of two conserved regions in the SARS-CoV-2 N gene in upper respiratory specimens and bronchoalveolar lavage. Under the reissued EUA, the test may also be used with pooled samples containing up to five individual upper respiratory specimens collected by a healthcare provider using individual vials containing transport media. 

With pooled sampling, Santa Fe Springs, California-based Applied BioCode said that its MDx-3000 instrument can run 2,820 samples a day.

Use of the assay is limited to labs CLIA-certified to perform high-complexity tests, according to the FDA.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.